Zhenya Lindgardt Sells 7,022 Shares of Sera Prognostics (NASDAQ:SERA) Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CEO Zhenya Lindgardt sold 7,022 shares of Sera Prognostics stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $2.00, for a total value of $14,044.00. Following the sale, the chief executive officer directly owned 837,848 shares in the company, valued at $1,675,696. The trade was a 0.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Zhenya Lindgardt also recently made the following trade(s):

• On Tuesday, September 8th, Zhenya Lindgardt sold 20,139 shares of Sera Prognostics stock. The stock was sold at an average price of $2.00, for a total value of $40,278.00.

Sera Prognostics Stock Performance

Shares of NASDAQ:SERA traded down $0.05 on Friday, hitting $2.00. The company’s stock had a trading volume of 26,356 shares, compared to its average volume of 49,381. The company has a market capitalization of $78.90 million, a price-to-earnings ratio of -2.99 and a beta of 0.98. Sera Prognostics, Inc. has a 12 month low of $1.56 and a 12 month high of $3.95. The stock’s 50-day moving average is $2.05 and its two-hundred day moving average is $2.02.

Sera Prognostics (NASDAQ:SERA) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.03). The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.07 million. Sera Prognostics had a negative net margin of 47,475.72% and a negative return on equity of 46.71%. Equities analysts expect that Sera Prognostics, Inc. will post -0.62 earnings per share for the current fiscal year.

Analysts Set New Price Targets

SERA has been the subject of a number of research analyst reports. Craig Hallum began coverage on shares of Sera Prognostics in a research note on Thursday, June 4th. They issued a “buy” rating and a $6.00 price target for the company. Weiss Ratings lowered shares of Sera Prognostics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $5.50.

Institutional Investors Weigh In On Sera Prognostics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Arkadios Wealth Advisors bought a new position in shares of Sera Prognostics during the 1st quarter valued at about $25,000. Lido Advisors LLC bought a new stake in shares of Sera Prognostics in the 3rd quarter worth approximately $68,000. Cetera Investment Advisers bought a new stake in shares of Sera Prognostics in the 4th quarter worth approximately $74,000. Two Sigma Investments LP acquired a new stake in Sera Prognostics during the third quarter valued at approximately $97,000. Finally, Qube Research & Technologies Ltd acquired a new stake in Sera Prognostics during the second quarter valued at approximately $92,000. 54.64% of the stock is currently owned by institutional investors.

Sera Prognostics Company Profile

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.